Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
Two weeks after I began induction therapy for multiple myeloma (MM), I developed a deep vein thrombosis (DVT). According to the study linked below, my SAVED score would have been 3 and therefore would have indicated that my risk of blood clot was high.
Newly diagnosed MM patients should understand that managing side effects from chemotherapy can increase their quality of life and quantity of life. Blood clots, both DVT and VTE, are a great example of a common side effect that is relatively easy to prevent.
Though the standard-of-care therapy to reduce the risk of blood clots are blood thinning medications such as Plavix, Eliquis and Xarelto, there are many evidence-based supplements and lifestyle therapies that can also reduce the risk of blood clots.
To lower my risk of blood clots I take:
In addition to frequent, moderate exercise and nutrition to also reduce my risk of blood clots.
Have you been diagnosed with multiple myeloma? Are you about to begin induction therapy and are wondering about your risk of DVT? Scroll down the page, post a question or comment and I will reply to ou ASAP.
“A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side effect of immunomodulatory therapies (IMiD) for multiple myeloma.
Researchers established the set of factors — based on a person’s
and how to score them so to better identify patients at risk for these clots, which could be prevented with anticoagulant (blood thinner) use…
“VTE is an under-recognized but frequently encountered complication … common in patients with multiple myeloma receiving IMiDs, and can cause disability, delay or complicate chemotherapy, and — in rare cases — be fatal…”
Researchers identified five clinical variables associated with a greater VTE risk:
The model identified approximately 30% patients at high risk. Depending on the dataset, these patients were 85% to 98% more likely (nearly twice as likely) compared to low-risk patients of having a VTE..”
“Background: Although venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), no validated clinical model predicts VTE in this population…
Conclusions: The SAVED score outperformed the current NCCN Guidelines in risk-stratification of patients with MM receiving IMiD therapy. This clinical model can help inform providers and patients of VTE risk before IMiD initiation and provides a simplified clinical backbone for further prognostic biomarker development in this population…”